studies

non squamous - mNSCLC - L1 - Wild Type (WT), atezolizumab plus carboplatin plus nab-paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-130 (WT), 2019 0.79 [0.64; 0.98] 0.79[0.64; 0.98]IMpower-130 (WT), 201910%679NAnot evaluable progression or deaths (PFS)detailed resultsIMpower-130 (WT), 2019 0.64 [0.54; 0.76] 0.64[0.54; 0.76]IMpower-130 (WT), 201910%679NAnot evaluable DORdetailed resultsIMpower-130 (WT), 2019 2.41 [1.27; 4.60] 2.41[1.27; 4.60]IMpower-130 (WT), 201910%292NAnot evaluable objective responses (ORR)detailed resultsIMpower-130 (WT), 2019 2.07 [1.48; 2.89] 2.07[1.48; 2.89]IMpower-130 (WT), 201910%673NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:19 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 176 - treatments: 865